Can You Take a GLP-1 Medication While Pregnant or Trying to Conceive?

What this means

GLP-1 medications for weight management are not approved for use in pregnancy, and the labels do not describe a safe dose or stage. The warning rests on two points. Weight loss is not a goal during pregnancy, and animal studies of semaglutide showed embryofetal death, structural abnormalities and altered growth at clinically relevant doses (Novo Nordisk, 2026). Human data are more reassuring but limited, as covered below.

PrimeCell’s GLP-1 program uses compounded medications, which are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The label statements in this article come from the approved products. There is no reason to assume a compounded version is safer for pregnancy, so the same caution applies.

Candidacy

Pregnancy status and pregnancy plans are part of deciding whether a GLP-1 medication is appropriate at all. This applies to anyone who could become pregnant, and also to people planning to conceive in the coming months, because of how long the drug lasts in the body. Pregnancy, a plan to conceive soon, or breastfeeding are reasons to pause the conversation about starting, not to start and sort it out later. Your physician decides candidacy after an evaluation.

Clinical evaluation

A physician evaluation before prescribing should cover:

• Pregnancy plans and current status. Whether you could be pregnant now, and whether you hope to conceive in the next several months to a year.
• Contraception. What you use, and whether it is a pill taken by mouth. This matters most with tirzepatide, described below.
• Medical history and current medications, including conditions that affect fertility, such as polycystic ovary syndrome, because weight change can alter ovulation.
• Baseline labs and measurements, chosen to fit your history.

Available options

If a pregnancy is likely within the year, the usual choices are to delay the medication, or to start it with a defined stopping point. For semaglutide, the label’s 2-month window means the last dose should come at least two months before you try to conceive (Novo Nordisk, 2026). The Zepbound label addresses stopping when a pregnancy is recognized, and the timing before conception is a question for your prescriber (Eli Lilly and Company, 2026). Nutrition counseling, activity, sleep and weight-management programs that do not use medication are alternatives, and your obstetrician or primary care physician may weigh in on timing.

If you are already taking a GLP-1 medication and a pregnancy test is positive, call your prescriber and your obstetric clinician the same day. Do not wait for the next scheduled visit.

Benefits, limitations and risks

Stopping before conception avoids exposing an early pregnancy to the drug. The cost is that weight regain can occur after stopping a GLP-1 medication, so a plan for nutrition, activity and follow-up helps. Whether to pause weight management before pregnancy is an individual decision that depends on your health and your obstetric history.

Tirzepatide adds a second issue. The Zepbound label states that it may reduce the effectiveness of oral hormonal contraceptives, and tells patients on those pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase (Eli Lilly and Company, 2026). Weight loss may also improve fertility in some people, which can make an unplanned pregnancy more likely than expected.

What the evidence shows

What it establishes: the labels’ pregnancy statements, the 2-month stopping window for semaglutide, and the oral contraceptive precaution for tirzepatide (Novo Nordisk, 2026; Eli Lilly and Company, 2026). A 2026 summary of a meta-analysis covering more than 47,000 pregnancies exposed to GLP-1 receptor agonists around conception or early in pregnancy reported no higher rates of several maternal complications, including gestational diabetes, preterm birth and preeclampsia (Jasper, 2026).

What it does not establish: that these medications are safe in pregnancy. The underlying studies were largely observational and varied in populations, drugs, doses and outcome measures. The same source notes that current guidance remains to stop before conception or when pregnancy is recognized (Jasper, 2026). Reassurance about an accidental early exposure is not permission to continue.

Recovery and next steps

If you are thinking about pregnancy, raise it at your first visit and ask your prescriber for a written stopping date. If you may already be pregnant, take a pregnancy test before the first dose. Bring your medication list, any recent labs and your contraception details to your evaluation. Dr. Chantasi will tell you whether starting now makes sense, and your obstetric clinician should be involved in any pregnancy plan. Individual results vary.